ANGPTL3 inhibitor

· Regeneron Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ANGPTL3 inhibitor, covering 2026-04-16 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease [Phase 2]

See pricing